JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that it has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7,132,570 (the “570 patent”) for Teva’s wakefulness product, NUVIGIL® (armodafinil) tablets. These settlements dismiss a pending appeal with the United States Court of Appeals for the Federal Circuit of a trial court decision that found the ‘570 patent to be valid and infringed.
Help employers find you! Check out all the jobs and post your resume.
